Kodiak Sciences Inc.
Zenkuda (tarcocimab tedromer)
diabetic retinopathy
Resolved
103days ago
Phase 3 readout · Mar 26, 2026
What's at stake
Phase 3 trial results for Zenkuda (tarcocimab tedromer) in diabetic retinopathy are due Mar 26, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Zenkuda now has a multi-indication Biologics License Application (BLA)-ready profile, and Kodiak intends to accelerate the BLA submission timeline.”